|
01 Sep 2025 |
Healthcare Global
|
Consensus Share Price Target
|
673.75 |
676.71 |
- |
0.44 |
buy
|
|
|
|
|
15 Dec 2022
|
Healthcare Global
|
ICICI Securities Limited
|
673.75
|
360.00
|
289.85
(132.45%)
|
Target met |
Buy
|
|
|
Company reiterates its focus on i) cost rationalisation, ii) talent upgrade and iii) digital transformation activities. It intends to stick to its core competency of oncology and does not intend to venture into other areas.
|
|
14 Nov 2022
|
Healthcare Global
|
Prabhudas Lilladhar
|
673.75
|
375.00
|
303.90
(121.70%)
|
Target met |
Buy
|
|
|
|
|
14 Nov 2022
|
Healthcare Global
|
ICICI Securities Limited
|
673.75
|
360.00
|
290.95
(131.57%)
|
Target met |
Buy
|
|
|
HealthCare Global Enterprises’ (HCG) Q2FY23 performance was broadly in line with our estimates. Revenues grew 19.3% YoY (+2.9% QoQ) to Rs4.2bn (I-Sec: Rs4.1bn) driven by increased occupancy levels.
|
|
11 Nov 2022
|
Healthcare Global
|
Axis Direct
|
673.75
|
330.00
|
290.95
(131.57%)
|
Target met |
Buy
|
|
|
We recommend a BUY with a rating on the stock with a target price of Rs 330/share.
|
|
15 Sep 2022
|
Healthcare Global
|
Geojit BNP Paribas
|
673.75
|
337.00
|
263.65
(155.55%)
|
Target met |
Buy
|
|
|
|
|
08 Sep 2022
|
Healthcare Global
|
Edelweiss
|
673.75
|
|
273.10
(146.70%)
|
|
Not Rated
|
|
|
Emphasis on oncology; long runway for growth
|
|
08 Sep 2022
|
Healthcare Global
|
ICICI Securities Limited
|
673.75
|
339.00
|
271.20
(148.43%)
|
Target met |
Buy
|
|
|
We met the management of HealthCare Global Enterprises (HCG) to discuss the company’s performance and strategy.
|
|
12 Aug 2022
|
Healthcare Global
|
Axis Direct
|
673.75
|
330.00
|
285.25
(136.20%)
|
Target met |
Buy
|
|
|
We recommend BUY with a target price of Rs 330.
|
|
12 Aug 2022
|
Healthcare Global
|
ICICI Direct
|
673.75
|
345.00
|
285.25
(136.20%)
|
Target met |
Buy
|
|
|
|
|
11 Aug 2022
|
Healthcare Global
|
Prabhudas Lilladhar
|
673.75
|
358.00
|
285.25
(136.20%)
|
|
Buy
|
|
|
|